OW 2025 4 - 7 November 2025

Improvements in Glycemic Parameters and Cardiovascular Risk Factors with Oral Semaglutide 25 mg

Authors :

Domenica Rubino¹; Oscar Birkhan²; W. Timothy Garvey³; Naveen Rathor²; Chaithra Shaji⁴; Sean Wharton^5,6,7,8; Ildiko Lingvay⁹

Affiliations

View Details Hide Details

{{ getPageNum(PDFPage) }}

Download infographic (.pdf)

Download infographic (.pdf)

Keywords

Obesity

Congress oral presentation

GLP-1 RA

Semaglutide (oral)

PHASE 3 (RCT)